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Background: The prevalence of negative symptoms in schizophrenic patients seems to be an important indicator
for treatment response and prognosis. Although negative symptoms have often been attributed to frontal lobe
anomalies, neuropsychological and anatomical findings do not explicitly support this assumption. Since knowledge
about the cerebral correlate of negative symptoms in schizophrenia might have a strong impact on therapeutic
and psychopharmacological interventions, we aimed to answer this question by investigating the relationship
between negative symptoms, neuropsychological functioning and cerebral volumes in schizophrenic patients.
Methods: Twenty schizophrenic patients and 32 healthy controls were examined using a neuropsychological test
battery for the assessment of temporal (mnestic) and frontal (executive) faculties. Volumetric measurements of
temporal (hippocampus and amygdala) and frontal (orbitofrontal, dorsolateral prefrontal, and anterior cingulate area)
brain areas were performed. Negative symptoms were assessed using the Scale for the Assessment of Negative
Symptoms (SANS).
Results: Schizophrenic patients performed worse than healthy controls in tests assessing verbal and visuospatial
learning and memory functions and on the Stroop interference task. After dividing the schizophrenic group in patients
with high and low SANS scores almost all of these deficits were restricted to the former group. There were no overall
group differences regarding cerebral subarea volumes. Overall negative symptoms were significantly correlated with
verbal memory functions but not with frontal lobe faculties.
Conclusions: Negative symptoms in schizophrenia could specifically associated with verbal memory deficits.
Keywords: Schizophrenia, SANS, Verbal memory, Magnetic resonance volumetryBackground
In 1985 Crow suggested a dichotomic concept for the
diagnosis of schizophrenia by dividing schizophrenic
disorders into type I- and type II-schizophrenia according
to the prevalence of either positive or negative symptoms
[1]. Since schizophrenic patients often show symptoms of
both dimensions and the psychopathology tends to change
in the course of disease [2], Crow’s approach did not
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unless otherwise stated.Nevertheless the concept of negative symptoms in
schizophrenia has attracted much attention, since negative
symptoms have been identified as important indicators for
treatment response and prognosis. Negative symptoms,
especially anhedonia and affective flattening, can be used as
predictors of long-term outcome [3,4]. Furthermore
negative symptomatology in schizophrenia was found
to intensify the severity of illness and strongly influence
global functioning [5]. Some authors found a specific
influence of negative symptoms on vocational (work
performance) and social functioning as well as functional
skills [6-8]. Furthermore negative symptoms have been
associated with social problem solving [9]. Besides, theyLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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responders were identified by a lesser degree of negative
symptomatology [10].
The first rating scale for the assessment of negative
symptomatology, the “Scale for the Assessment of Negative
Symptoms” (SANS), was developed by Andreasen in
the early 1980s [11,12]. The SANS became the standard
instrument for rating the extent of negative symptoms in
schizophrenia. It defines five symptom complexes: affective
flattening, impoverishment of language and thinking
(alogia), reduced drive (avolition/apathy), the inability
to feel happy (anhedonia/asociality) and disturbance
of attention.
Negative symptoms might be differentiated from positive
symptoms by a distinct pathological process. Traditionally
negative symptoms in schizophrenia have been linked
to frontal lobe anomalies, mainly due to the frequently
described relationship between negative symptoms
and hypofrontality while in a resting state or during the
processing of cognitive tasks [13-18].
Due to these findings many studies regarding the
correlation between negative symptoms and cognitive
dysfunctions in schizophrenia have hypothesized and
verified an inverse relationship between the extent of
negative symptoms and so-called frontal lobe deficits.
Inverse correlations were most often found with paradigms
assessing logical thinking and categorization, e.g. the
Wisconsin Card Sorting Test as well as indicators of
verbal fluency [19-23].
Nevertheless inverse correlations with a variety of
other cognitive dysfunctions have also been found.
Pronounced negative symptoms have been linked to
stronger impairments in recognition memory, psychomotor
speed, attention or visuospatial abilities [22,24-27].
Several morphometric studies support the link between
negative symptoms in schizophrenia and frontal lobe
impairment. Reduced frontal lobe volumes have been
found in correlation with anhedonia and the apathy
level of schizophrenic patients, which are core symptoms
of schizophrenic negative symptomatology [28,29].
The extent of negative symptoms was also significantly cor-
related with smaller orbitofrontal, left insular, dorsolateral
prefrontal regions, bilaterally in the medial frontal, anterior
cingulate, inferior frontal and superior temporal regions
gray matter volume [30-32] as well as reductions in
prefrontal gray and white matter [21,33,34]. Asami
and coworkers found a positive correlation between
frontolimbic and left superior temporal gyrus gray
matter volume reduction and negative symptoms [35].
Reduced gray matter volume in the middle prefrontal
gyrus (Brodmann area 9/46 of frontal association cortex)
as a correlate of negative symptoms have also been shown
by other authors [36-38]. Following Talati and Hirsch the
medial prefrontal gyrus, appendant to the dorsolateralprefrontal cortex, seems to be associated with executive
mechanisms and decision- making abilities as a higher
processing unit and might thereby modulate negative
symptoms [39]. A study using diffusion tensor imaging, a
method to assess the integrity of neural fiber tracks,
suggests an association between impaired white matter
integrity in the inferior frontal region of schizophrenic
patients and the severity of negative symptoms [40].
However, in analogy to the neuropsychological findings,
these results do not seem to be unambiguous, since
other studies reported correlations between negative
symptomatology and anomalies in other brain areas,
especially the temporal regions, with the superior
temporal gyrus [34,41-43] and the hippocampus being
most often reported [44].
So far distinct conclusions concerning the relationship
between cognitive dysfunctions and negative symptoms
in schizophrenia especially with respect to the cerebral
correlate cannot be drawn. Based on present findings
anomalies connected to the frontal and temporal lobes
are primarily discussed.
A disadvantage of many neuropsychological studies
examining the association between negative symptoms
and neuropsychological dysfunctions is the restriction to
a single cognitive faculty or a group of functions related
to only one brain region, especially the frontal lobes.
Furthermore only few studies have combined a neuro-
psychological assessment with a morphometric approach
to explore the relationship with negative symptoms.
To address this question this study aims to investigate
the cognitive and cerebral correlates of negative symptom-
atology in schizophrenia.
Schizophrenic patients and healthy controls were
examined using the SANS, volumetric MRI-measures
of different frontal and temporal brain structures and
a comprehensive neuropsychological test battery covering
frontal lobe (executive) as well as mediotemporal
(memory) functions to assess the relationship between
negative symptoms, neuropsychological deficits and struc-
tural brain anomalies in patients with schizophrenia.
Methods
Participants
Approval from the Albert-Ludwigs university ethics
committee Freiburg was obtained before onset of the
study. 20 patients with DSM-IV-defined schizophrenia, 8
female, 12 male, hospitalised for acute exacerbation
and adjusted to medication, were identified among
the in-patients of the Department of Psychiatry and
Psychotherapy of the University Hospital of Freiburg.
The clinical diagnosis of schizophrenia was made by
experienced senior consultant psychiatrists based on a
structured interview according to DSM-IV criteria.
After giving informed written consent to participate
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study. All patients received a full neurological and
medical history and examination as well as routine
blood tests and EEG examinations to exclude any
other medical or neurological disorder. Patients were
excluded if they had any other DSM-IV axis I diagnosis or
met criteria for substance abuse within the previous
6 months. To keep the sample homogenous by avoiding
an overlap to psychogeriatric problems the study group
was restricted to patients under the age of 45 years and
normal IQ range. Clinical state of patients was assessed
using the Brief Psychiatric Rating Scale (BPRS) [45] and
the Scale for the Assessment of Negative Symptoms
(SANS) [11]. The overall severity of psychiatric disturbance
for the present state as well as for the past two years was
measured using the Global Assessment Scale [46]. The
Phillips scale [47] was used to assess the premorbid
adjustment of the patients. The history of illness was
documented in regard to the age of onset of clinical
symptoms, the duration of schizophrenia, the total
amount of time hospitalized for schizophrenia and the
number of psychotic episodes (Table 1). Confounding
variables like family history, any history of meningitis or
encephalitis or other brain injuries as well as the present
medication were documented. Chlorpromazine-equivalents
(CPE) were calculated for the current antipsychotic
medication. Due to the vague informations provided by
the patients and carers lifetime exposure to antipsychotic
medication could not be measured. 32 control subjects, 12
female, 20 male, were recruited via announcements and
group matched according to age, sex and school education
(Table 1). Exclusion criteria were identical for the patient
and control group. In addition, volunteers with a positive
personal or family history of any psychiatric disorder were
excluded from participation.Table 1 Demographic data and clinical characteristics of the s
schizophrenic group with a low SANS score, and the control g
Demographic data/clinical characteristics
Age (in years)
School education (in years)
Sex (female/male)
Age of onset of clinical symptoms (in years)
Duration of schizophrenia (in months)
Number of psychotic episodes
Total amount of time hospitalized for schizophrenia (in weeks)
BPRS
Positive family history for psychiatric disorders in 1st and 2nd grade dependa
Chlorpromazine-equivalents
1Pearson’s Chi-Square.
(Spearman rank correlation, * p ≤0,05, ** p ≤0,01).Neuropsychological assessment
A comprehensive neuropsychological test battery was
administered by a trained and experienced psychologist.
The test battery covered the following neuropsychological
functions: verbal memory/learning, visual memory/
learning, concentration, working memory, verbal fluency,
verbal intelligence, interference and abstraction/cognitive
flexibility.
Verbal memory/learning were assessed using the
subtest Logical Memory, trial 1 and 2, of the revised
Wechsler Memory Scale (WMS-R, German edition)
[48] and the wordlist of the Nürnberg’s Aging Inventory
(Nürnberger Altersinventar, NAI) [49]. The subtest Visual
Reproduction, trial 1 and 2, of the WMS-R (German
edition) was administered to measure visual memory/
learning. Working memory and concentration were
assessed using the subtest “digit span” of the Wechsler
Adult Intelligence Scale (German edition) [50]. Interference,
response inhibition, abstraction and cognitive flexibility
were evaluated using the Stroop-Test (German version)
[51] and the Wisconsin Card Sorting Test (WCST,
pc-edition) [52]. The subtest “Information” of the
HAWIE-R [50] was administered to measure verbal
intelligence. Verbal fluency was assessed using the verbal
fluency test of the Performance Test System [53].
The tests were administered after patients had reached
subacute status to avoid confounding psychotic symptoms.
The neuropsychological assessment lasted between 1.5
and 2 h.
Imaging and measurements
Within two weeks to the neuropsychological assessment
MRI images were obtained at the Department of Radiology
at the University of Freiburg on a 2 T whole-body system
(Medspec S200, Bruker BioSpin MRI, Ettlingen - Germany)chizophrenic group with a high SANS score, the






Mean SD Mean SD Mean SD F-value
27,90 6,03 30,40 7,78 28,22 5,83 0,53
12,30 1,25 12,20 1,32 12,13 1,50 0,06
7/3 5/5 22/10 1,301
24,22 3,80 26,10 6,06 0,63
49,78 54,48 58,90 51,31 0,03
2,11 2,42 2,00 2,00 0,30
19,11 19,66 24,80 27,77 0,01
45,50 16,86 27,60 8,57 7,36**
nt 8 10 4,21
10 10 0,81
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coronal images were acquired to screen for brain pathology.
For volumetric assessment a T1-weighed 3-D-data set
was acquired using a modified driven equilibrium
Fourier transfer sequence (MDEFT) [54] with the following
parameters: TR =17 ms, TE =5.5 ms, flip angle =30, matrix
256×192×92, FOV =24×23×18 cm3. The images were
transferred to a UNIX Sun workstation via a network
(Sun Microsystems, Mountain View, California, USA).
Volumetric measurements of the hippocampus, the
amygdala, the dorsolateral prefrontal cortex (DLPFC)
and the orbitofrontal cortex (OFC) were performed for
both hemispheres by a blinded rater after establishing a
good reliability using the interactive software program
MRreg [55]. The volumetric assessment followed well
established and published protocols by our group [56].
Results of structural imaging as well as functional imaging
aspects of parts of the study sample have been published
in previous papers [57-61].
Statistical analysis
Demographics
To compare both groups concerning age, education and
sex Student’s t-Tests and a Chi Square Test were employed,
respectively.
Group comparisons – neuropsychology
The neuropsychological test scores were converted to
Z-scores (standard equivalents) and single test values
covering the same neuropsychological faculty were averaged
to define the following factors: verbal learning/memory,
visuo-spatial learning/memory, working memory/concen-
tration and frontal lobe functioning. Schizophrenic patients
and healthy controls were compared concerning the four
different neuropsychological factors using multivariate
analyses of covariance (MANCOVA) with CPE as covariate
to control for medication effects. Following this post hoc
multivariate analyses of covariance were calculated for each
single neuropsychological test score, again considering CPE
as covariate. In a second step a median split on the SANS
score was performed to distinguish schizophrenic patients
with high and with low SANS scores. The Median split
rendered a clear cut between patients concerning negative
symptoms, since the SANS global score in the low score
group ranged from 0 to 16 and in the high score group
from 24 to 74. The two groups differ significantly in the
BPRS Score (Student’s t-Test) so that the median split is
also relevant in relation to the BPRS. The statistical
procedure explained above was repeated comparing
schizophrenic patients with a high SANS score (HSS),
schizophrenic patients with a low SANS score (LSS) and
healthy controls, using multivariate analyses of variance
(MANOVA). Post hoc analysis was done using Bonferroni
correction.Group comparisons – volumetric data
The volumes of the hippocampus, the amygdala, the
anterior cingulate cortex, the DLPFC and the OC
were corrected for differences in total brain volumes
following earlier publications by our group [61-64].
The different volumes were also analysed in the two
steps described above using Repeated Measurements
ANOVA with hemisphere as intra-subject factor and
CPE as covariate.
Correlation analyses
Correlations between psychopathology, neuropsychological
results and volumetric data were computed for schizo-
phrenic patients only using Spearman rank-correlation.
All data were analyzed using SPSS for Windows
(Release 11.5). A p-value of p ≤ .05 was chosen as the
criterion of significance for all statistical calculations.
Results
Patient and control group
The overall group of schizophrenic patients as well as
the subgroup of patients with high and low negative
symptom scores were matched in terms of age, sex and
duration of education. There were no differences between
the two schizophrenic subgroups in terms of duration of
schizophrenia, age of onset of clinical symptoms, total
amount of time hospitalized for schizophrenia and
number of psychotic episodes (see Table 1). In relation to
the BPRS schizophrenic patients with a high SANS
score differ significantly from patients with a low SANS score.
The BPRS scores for the patients with a high SANS score were
45,5 and a BPNRS scores for the patients with low SANS
score were 27,6 points (F =7,3, p <0,01).
Group comparisons - neuropsychological performance
Schizophrenic patients vs. healthy controls
UNIANOVA showed a significantly worse performance
of the schizophrenic patients compared to the healthy
controls concerning verbal and visuospatial learning/
memory (F =9,52, p ≤0,01; F =11,49, p ≤0,01). No differ-
ences in performance were found for working memory/
concentration and frontal lobe functioning (F =0,28,
n.s.; F =2,11, n.s.). Considering the single neuropsycho-
logical parameters UNIANOVAs showed a significantly
worse performance of the schizophrenic patients com-
pared to the healthy controls concerning WMS-R, Logical
Memory immediate recall and delayed recall, NAI
Wordlist immediate recall trials 2 and 3 as well as
delayed recall, WMS-R, Visual Reproduction immediate
and delayed recall and Stroop – Interference. No medica-
tion effects were found. Mean raw scores of the neuro-
psychological parameters for the schizophrenic and the
control group as well as significance of results are shown
in Table 2.
Table 2 Mean raw scores of the neuropsychological
parameters for the schizophrenic and the control group
as well as F- and significance of results
Neuropsychological test Controls Schizophrenics
Mean SD Mean SD F-value1
WMS-R, logical memory I 33,28 6,97 39,00 26,10 10,97**
WMS-R, logical memory II 29,63 8,54 37,00 20,40 13,73**
NAI, wordlist trial I 8,22 2,79 7,05 1,76 3,15
NAI, wordlist trial II 11,84 2,48 9,60 2,11 6,33*
NAI, wordlist trial III 13,22 1,75 11,90 1,86 6,30*
NAI, wordlist delayed 11,91 3,38 9,65 3,56 4,09*
HAWIE-R, information 18,94 3,63 15,65 3,84 2,18
WMS-R, visual reproduction I 39,47 1,68 37,75 2,47 7,50**
WMS-R, visual reproduction II 39,13 2,20 36,05 4,76 12,91**
HAWIE-R, digit span 17,25 4,53 15,05 2,96 0,34
HAWIE-R, digit span forward 8,78 2,09 8,20 1,82 0,09
HAWIE-R, digit span backward 8,47 2,85 6,85 1,73 1,34
Stroop interference 63,56 11,97 87,35 23,28 10,23**
Verbal fluency 41,34 15,51 30,40 8,62 3,31
WCST, ntcc1 12,26 3,82 16,28 10,16 0,23
WCST, perseverative reactions 12,39 12,60 19,50 17,52 1,02
WCST, perseverative errors 10,87 10,17 17,33 14,48 1,28
1based on the Z-scores of the different neuropsychological test parameters.
WCST, ntcc1 =WCST, no. of trials to complete category 1.
(Spearman rank correlation, * p ≤0,05, ** p ≤0,01).
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schizophrenic patients with a low SANS score vs. healthy
controls
The MANCOVAS showed significant group effects
for verbal and visuospatial learning/memory (F =8,18,
p ≤0,01; F =5,67, p ≤0,01). Post-hoc analysis indicated a
worse performance of the schizophrenic HSS patients
compared to the schizophrenic patients with a LSS and
the controls concerning verbal learning/memory (mean
difference =0,73, p ≤0,05; mean difference =1,08, p ≤0,01).
Concerning visual learning/memory schizophrenic
patients with a HSS score achieved lower scores than con-
trols (mean difference =0,78, p ≤0,01). No differences in per-
formance were found for working memory/concentration
and frontal lobe functioning (F =0,15, n.s.; F =1,55, n.s.).
No medication effects were found.
We found significant group effects for WMS-R,
Logical Memory immediate and delayed recall, NAI
Wordlist immediate recall trial 2–3 and delayed re-
call, HAWIE-R, subtest “information” WMS-R, Visual
Reproduction immediate and delayed recall, Stroop –
Interference, verbal fluency, WCST, no. of trials to complete
category 1 and no. of perseverative errors.
Post-hoc analyses indicated a worse performance of
the schizophrenic patients with a HSS compared to thecontrols concerning WMS-R, Logical Memory immediate
recall and delayed recall, NAI Wordlist immediate recall,
trial 2 and trial 3 and WMS-R, NAI Wordlist delayed
recall, HAWIE-R, subtest “information”, WMS-R, Visual
Reproduction delayed recall, Stroop – Interference and
WCST, no. of trials to complete category 1. Schizophrenic
patients with a HSS also achieved lower test scores than
schizophrenic patients with a LSS concerning WMS-R,
Logical Memory delayed recall. Schizophrenic patients
with a LSS showed a worse performance than controls in
regard to WMS-R, Visual Reproduction immediate recall,
Stroop – Interference and WCST, perseverative errors.
The mean raw scores of the neuropsychological tests for
the two schizophrenic groups and the control group as
well as significance of results are shown in Table 3.
Group comparisons – volumetric findings
Schizophrenic patients vs. healthy controls
In 10 control subjects the quality of structural 3-D-data
sets was insufficient for further analysis. There were no
significant differences between the schizophrenic and
the control group with respect to total brain volume
(tbv; F =0,89; p = n.s.) as well as the volumes of the
hippocampus (F =0,40; p = n.s.), the amygdala (F =0,13;
p = n.s.), the anterior cingulate cortex (F =0,00; p = n.s.),
the DLPFC (F =0,79; p = n.s.) or the OC (F =0,69; p = n.s.).
Neither medication effects (hippocampus: F =0,91;
amygdala: F =0,36; anterior cingulate cortex: F =0,39;
DLPFC: F =0,15; OC: F =0,33; tbv: F =0,36; p = n.s.) nor
any interaction with medication (hippocampus: F =3,11;
amygdala: F =2,57; anterior cingulate cortex: F =0,00;
DLPFC: F =1,64; OC: F =0,37; p = n.s.) or group
(hippocampus: F =0,42; amygdala: F =2,01; anterior
cingulate cortex: F =0,07; DLPFC: F =0,01; OC: F =0,05;
p = n.s.) were observed. For the hippocampus a significant
effect for hemisphere was found (F =15,47; p ≤0,01), indi-
cating a greater right volume of the hippocampus. The
same was true for the amygdala (F =5,51; p ≤0,05) and the
anterior cingulate cortex (F =4,13; p ≤0,05). An effect for
hemisphere was also found for the DLPFC with a greater
left than right DLPFC (F =6,81; p ≤0,05). For the OC
hemisphere did not show any effects (F =2,16; p = n.s.).
The volumetric data for the two schizophrenic groups and
the control group are shown in Figure 1.
Schizophrenic patients with a high SANS score vs.
schizophrenic patients with a low SANS score vs. healthy
controls
The UNIANOVA did not show any group effects for total
brain volume (F =0,43; p = n.s.). Repeated Measurements
ANOVA revealed no group effects (F =0,18; p = n.s.) for
the hippocampus. There was a significant effect for hemi-
sphere (F =5,89; p ≤0,05), indicating a greater right volume
of the hippocampus, and a significant interaction with
Table 3 Mean raw scores of the neuropsychological parameters for the schizophrenic group with a high SANS score (S1),
the schizophrenic group with a low SANS score (S2), and the control group (C) as well as significance of results




Controls (C) Post-hoc analyses
Mean SD Mean SD Mean SD F-value1 S1 vs. S2* S2 vs. C* S1 vs. C*
WMS-R, logical memory I 22,80 5,73 29,40 6,15 33,28 6,97 6,58** n.s. n.s. p ≤0,01
WMS-R, logical memory II 15,70 5,98 25,10 5,61 29,63 8,54 8,34** p ≤0,05 n.s. p ≤0,01
NAI, wordlist trial I 6,20 1,03 7,90 1,97 8,22 2,79 1,97 n.s. n.s. n.s.
NAI, wordlist trial II 8,80 1,93 10,40 2,07 11,84 2,48 4,97** n.s. n.s. p ≤0,01
NAI, wordlist trial III 11,00 1,76 12,80 1,55 13,22 1,75 4,22** n.s. n.s. p ≤0,01
NAI, wordlist delayed 7,90 3,76 11,40 2,41 11,91 3,38 3,7** n.s. n.s. p ≤0,01
HAWIE-R, information 14,80 4,42 16,50 3,17 18,94 3,63 5,5** n.s. n.s. p ≤0,01
WMS-R, visual reproduction I 37,90 2,96 37,60 2,01 39,47 1,68 3,27* n.s. p ≤0,05 n.s.
WMS-R, visual reproduction II 34,60 6,29 37,50 1,90 39,13 2,20 5,36** n.s. n.s. p ≤0,01
HAWIE-R, digit span 15,60 3,17 14,50 2,80 17,25 4,53 1,89 n.s. n.s. n.s.
HAWIE-R, digit span forward 8,20 2,04 8,20 1,69 8,78 2,09 1,27 n.s. n.s. n.s.
HAWIE-R, digit span backward 7,40 1,84 6,30 1,49 8,47 2,85 2,34 n.s. n.s. n.s.
Stroop interference 84,00 23,08 90,70 24,22 63,56 11,97 7,85** n.s. p ≤0,01 p ≤0,01
Verbal fluency 30,10 9,83 30,70 7,76 41,34 15,51 2,75 n.s. n.s. n.s.
WCST, ntcc1 19,60 11,65 12,13 6,36 12,26 3,82 7,07** n.s. n.s. p ≤0,01
WCST, perseverative reactions 14,40 10,16 25,88 23,01 12,39 12,60 2,46 n.s. n.s. n.s.
WCST, perseverative errors 13,10 8,50 22,63 18,94 10,88 10,17 2,77* n.s. p ≤0,05 n.s.
1based on the Z-scores of the different neuropsychological test parameters.
n.s. = not significant.
WCST, ntcc1 =WCST, no. of trials to complete category.



































































Figure 1 Mean corrected volumes of the amygdalae, hippocampi, anterior cingulate cortices, DLPFC and OC for the schizophrenic group
with a high SANS score, the schizophrenic group with a low SANS score, and the control group [error bar indicates Standard error].
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http://www.biomedcentral.com/1471-244X/14/326group (F =3,37; p ≤0,05). For the anterior cingulate cortex
there were no statistically significant effects for group
(F =0,56; p = n.s.) or the interaction between group and
hemisphere (F =0,12; p = n.s.), but a significant effect for
hemisphere corresponding to the lateralization of the
hippocampus (F =6,81; p ≤0,05). No group (F =0,54;
p = n.s.) or hemisphere (F =2,52; p = n.s.) effects or an
interaction between group and hemisphere (F =0,68;
p = n.s.) were found for the amygdala. The same was true
for the DLPFC (group: F =1,28; p = n.s.; hemisphere:
F =3,13; p = n.s.; interaction with group: F =0,71; p = n.s.)
and the OC (group: F =2,45; p = n.s.; hemisphere: F =1,55;
p = n.s.; interaction with group: F =0,32; p = n.s.). Post hoc
analyses did not show any significant differences between
any of the three groups in regard to total brain volume,
the volume of the hippocampus, the amygdala, the anterior
cingulate cortex, the DLPFC and the OC.Table 4 Significant correlations between neuropsychological
Affective flattening Alogia paralogia A
WMS-R, logical memory I −0,33 −0,35
WMS-R, logical memory II −0,57** −0,52*
NAI, wordlist trial I −0,39 −0,33
NAI, wordlist trial II −0,48* −0,57**
NAI, wordlist trial III −0,57** −0,48*
NAI, wordlist delayed −0,51* −0,45*
HAWIE-R, information 0,04 0,00
WMS-R, visual reproduction I 0,06 0,15
WMS-R, visual reproduction II −0,34 −0,17
HAWIE-R, digit span 0,28 0,03
HAWIE-R, digit span forward 0,10 −0,04
HAWIE-R, digit span backward 0,42 0,10
Stroop interference −0,07 −0,04
Verbal fluency 0,03 −0,07
WCST, ntcc1 0,05 0,32
WCST, perseverative reactions −0,04 −0,13
WCST, perseverative errors −0,08 −0,13
Total brain volume 0,33 0,31
Hippocampus right 0,44 0,24
Hippocampus left 0,22 0,36
Amygdala right 0,03 0,18
Amygdala left 0,12 0,06
Anterior cingulate cortex right 0,02 −0,00
Anterior cingulate cortex left −0,11 0,06
DLPFC right 0,23 0,01
DLPFC left 0,12 0,12
OC right 0,36 0,35
OC left 0,15 0,35
(Spearman rank correlation, * p ≤0,05, ** p ≤0,01).Correlation analysis
Correlations between SANS sub scores and SANS global
score, respectively, and neuropsychological performance
are primarily found for indicators of verbal learning/
memory. There were no significant correlations between
the volumes of the hippocampus, the amygdala, the
DLPFC and the OC on the one hand and scores of
negative symptoms on the other hand. A positive
correlation between total brain volume and the SANS
sub score attention was found. Results of correlation
analysis can be seen in Table 4.
Discussion and conclusions
In this study, schizophrenic patients displayed pronounced
impairments in verbal and visuospatial memory as well as
deficits concerning response inhibition. Dividing the
schizophrenic group in patients with low and high SANStest results and SANS subscores/SANS global score
bulia apathy Anhedonia associality Attention SANS global score
−0,32 −0,49* −0,38 −0,46*
−0,49* −0,59** −0,54* −0,66**
−0,46* −0,29 −0,39 −0,42
−0,25 −0,34 −0,47* −0,51*
−0,35 −0,34 −0,37 −0,54*
−0,33 −0,38 −0,39 −0,50*
0,04 0,10 −0,18 −0,03
−0,09 0,00 0,02 0,09
−0,30 −0,15 −0,23 −0,23
0,10 0,11 −0,13 0,13
0,04 0,12 −0,02 0,05
0,12 0,01 −0,25 0,17
−0,06 −0,19 0,01 −0,07
−0,08 −0,30 −0,39 −0,10
−0,03 −0,06 0,03 0,11
−0,28 −0,26 −0,21 −0,26
−0,29 −0,27 −0,20 −0,28
0,38 0,25 0,63* 0,41
0,12 0,14 0,10 0,28
0,10 0,39 0,19 0,26
0,03 0,23 0,31 0,19
0,01 −0,15 −0,02 0,15
0,23 0,16 0,44 0,24
−0,15 −0,02 −0,08 0,02
0,26 −0,21 −0,13 0,20
0,10 −0,16 0,09 0,19
0,33 0,24 0,07 0,46
0,33 0,28 0,38 0,43
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executive impairments in the HSS patients, whereas the
LSS patients were relatively unimpaired. Correlations
between SANS sub scores and global score, respectively,
were mainly found with indicators of verbal memory.
Anomalies in frontal or temporal brain regions or associa-
tions with neuropsychological variables were not found.
These findings underline the association between negative
symptomatology in schizophrenia and pronounced neuro-
psychological deficits and emphasise the relevance of verbal
memory impairments.
The impact of negative symptoms on neuropsychological
impairment in schizophrenia
The neuropsychological findings in our schizophrenic
group are in general agreement with findings of other
studies showing specific deficits concerning learning and
memory in schizophrenic patients [65].
Although the prevalence of executive dysfunctions
in schizophrenia is estimated to be around 90% [66]
we could not confirm impairments in frontal lobe
functioning with the exception of difficulties in response
inhibition as assessed by the Stroop task. Results of a
study by Hutton [67] indicates, that the type of executive
impairment might depend on the phase of illness. At the
beginning of the disease process patients display deficits
of planning and strategical thinking, whereas in chronic
patients this shifts towards impairments concerning
categorization and flexibility as assessed by the WCST.
Since on average our schizophrenic patients have had only
2 schizophrenic episodes, this might explain the negative
WCST results.
Studies have already shown the impact of negative
symptomatology on certain neuropsychological functions in
schizophrenic patients. Our results confirm the association
between negative symptomatology in schizophrenia and
pronounced neuropsychological deficits already found by
others [22,26,27,29]. Patients with a high SANS global score
showed significantly more pronounced deficits especially
concerning mnestic functioning than patients with a low
SANS global score.
These results underline the close connection between
negative symptomatology and verbal memory on the
background of macroscopically unchanged structures in
frontal and temporal cerebral areas. This is in contrast
to other studies, which primarily reported a correlation
between negative symptoms and executive functioning,
sometimes associated with the corresponding structural
changes in frontal lobe regions [19,20,22].
Following the general line of thought a correlation
between negative symptoms and executive – or so called
frontal lobe - impairments would have been expected,
since negative symptoms are assumed to be a consequence
of frontal lobe impairment [68]. On the other hand Hilland coworkers observed an amplifying effect of negative
symptomatology in combination with disorganized
behaviour on learning and memory deficits in schizophrenic
patients, thereby confirming the results of this study [69].
The schizophrenic group in this study showed a relatively
high level of functioning in the neuropsychological
categories studied here. The patients showed almost
no executive impairments and no deficits concerning
concentration and working memory. Patients with high
and low negative symptoms could mainly be separated by
their memory performance, even HSS patients could
adhere their executive functioning. Memory, especially
concerning the verbal modality, should be regarded as left
temporal lobe functions in the majority of people and
might be more vulnerable in regard to the cerebral
changes associated with a schizophrenic disorder than
other neuropsychological functions.
Interestingly the schizophrenic patients in this study
did neither not show any change in the examined
cerebral structures nor any relationship between neuro-
psychological measures and the examined anatomical
faculties. Current findings report contradictory results.
Some studies have found smaller volumes of brain
structures in schizophrenic patients, especially of the
hippocampus, the amygdala and the anterior cingulate
cortex [36,70-72]. Whereas other findings could neither find
any volumetric differences in the hippocampus-amygdala-
complex nor in the different frontal lobe regions [73,74].
Possible explanations for these inconsistencies might
be differences in the kind of volume assessment, e.g.
morphometric measurements using SPM or manual
tracing of a structure according to validated protocols.
However, such contradictions could also relate to the
fact that the different study samples vary in terms of
underlying pathophysiology [75]. Especially in schizophrenia
it is extremely difficult to assess a sufficiently homogenous
population to be able to generalize findings to the results of
other studies. The coexistence of normal volumes of the
examined frontal and temporal faculties on the one hand
and memory impairments as well as deficits in response
inhibition on the other hand allow different interpretations.
A functional recovery may have taken place before the
structural regeneration. It could also be the case, that the
macroscopically normal volume of a certain brain area
might mask more subtle histological alterations or
functional anomalies not related to structural change.
This leaves the question of the organic basis for the
observed deficits and especially the correlation between
negative symptomatology and verbal memory impairments
unanswered. As macro-structural aberrations do not seem
to be the organic basis for the correlation between negative
symptoms and verbal memory impairment, biochemical or
physiological mechanisms as the underlying common
cerebral correlate have to be considered. Glutamate seems
Hornig et al. BMC Psychiatry 2014, 14:326 Page 9 of 11
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The glutamate hypothesis of schizophrenia was developed
after it had been recognized that Phencyclidine (PCP)
leads to an exacerbation of symptoms in schizophrenic
patients [76] and produces a schizophrenia-like state in
normal individuals with positive and negative symptoms
as well as cognitive disturbances [77,78]. PCP serves as a
noncompetitive antagonist at the glutamatergic NMDA
receptor [79]. Glutamate acts via different receptor types,
but so far the main focus of the relationship between
glutamate and schizophrenia has been on the NMDA
receptor. It plays a major role in long-term potentiation, a
synaptical process involved in memory formation [80].
Besides its role concerning mnestic functions glutamate
also affects schizophrenic negative symptomatology. Using
D-serine, a full agonist at the glycine modulatory site
of the NMDA receptor, Tsai et al. (1998) have found
significant improvements in negative symptoms, psychosis,
and executive function as measured by the cognitive
subscale of the Positive and Negative Syndrome Scale
(PANSS) and performance on the Wisconsin Card
Sorting Test [81]. Similarly D-cycloserine, a partial agonist
at the glycine modulatory site of the NMDA receptor, has
led to a diminution of negative symptomatology either
alone or added to conventional antipsychotics [82,83].
Considering these results glutamate might be the latent
variable underlying the relationship between mnestic defi-
cits and negative symptomatology observed in this study.
Methodological issues
Some methodological issues have to be considered. Dividing
a group by a median split could be criticised due to the
artificial allocation of patients to a certain group, who would
otherwise be described on a continuum. In this study the
highest SANS score of the LSS group was 16, whereas the
lowest SANS score of the HSS group was 24. This yielded a
clear differentiation of schizophrenic patients with low and
high negative symptoms.
The chosen neuropsychological tests had to exist in a
German version thereby limiting the range of possible
assessment procedures. Nevertheless only those tests
were taken that are profoundly validated and broadly
accepted as neuropsychological diagnostic tools. The
neuropsychological tests were administered by a trained
and experienced neuropsychologist, guaranteeing an
adherent administration. The volumetric method used is
sound and has been described in a number of other
publications [59-61]. However, according to our measure-
ment protocol we did not separate gray from white matter
and thus we cannot commend on whether there might have
been a volume reduction of one of these compartments in
the different groups.
The patient assessment was done by an experienced
team of clinicians on a ward specialized on the treatmentof chronic schizophrenia and the psychopathology was
validated and quantified using internationally accepted
psychometric tools.
Summary
In summary in this study we present data of a carefully
diagnosed sample of patients with schizophrenia and
control subjects. Following broad and parallel clinical,
psychometric and MRI-based volumetric assessment of
temporal and frontal lobe areas we did not identify
group overall volumetric differences in frontal or
temporal brain volumes. High scores of negative
symptoms were categorically and dimensionally related in
particular to verbal memory deficits rather than to dysexe-
cutive dysfunction. Therefore the main finding of this
study is, that from a functional point of view and in
spite of absence of clear macroscopic volumetric
brain differences negative symptoms are more related
to left temporal brain properties (verbal memory deficits)
than to frontal lobe dysfunction (dysexecutive symptoms).
Further research should specifically adress this important
research question and should possibly test the putative role
of temporal glutamatergic dysfunction and its relationship
to negative symptoms.
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